Related Experiment Video
Updated: Sep 16, 2025
05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
358
GPs' perspectives on GLP-1RAs for obesity management: a qualitative study in England
Sabrina Keating1, Cervantée Wild2, Jadine Scragg3
1University of Oxford, Nuffield Department of Primary Care Health Sciences, Radcliffe Primary Care Building, Oxford, UK.
Summary
General practitioners (GPs) in England support using glucagon-like peptide-1 receptor agonists (GLP-1RAs) for obesity management. However, they worry about resource limitations and ensuring these drugs are part of a holistic approach.
Area of Science:
- General Practice
- Pharmacology
- Public Health
Background:
- Rising obesity rates necessitate effective primary care treatments.
- General practitioners (GPs) in the NHS report low confidence in current obesity management options.
- Glucagon-like peptide-1 receptor agonists (GLP-1RAs) show promise for weight management but lack primary care pathways.
Purpose of the Study:
- To explore NHS GPs' perspectives on GLP-1RAs for weight management.
- To understand potential challenges and facilitators for integrating GLP-1RAs into primary care.
- To assess GP views on the role of GLP-1RAs within broader obesity strategies.
Main Methods:
- 25 semi-structured interviews with GPs across England.
- Purposive sampling to ensure diverse geographical and socioeconomic representation.
- Thematic analysis of interview data collected between April-July 2024.
Main Results:
- GPs generally hold positive views on implementing GLP-1RAs for weight management.
- Concerns exist regarding resource limitations and managing patient requests for prescriptions or private use.
- Worries were raised about GLP-1RAs potentially oversimplifying obesity treatment and detracting from broader determinants.
Conclusions:
- GPs see GLP-1RA integration as valuable but require adequate resources for successful implementation.
- Effective integration necessitates GLP-1RAs being part of a comprehensive, holistic obesity management strategy.
- Addressing GP concerns is crucial for strengthening support for GLP-1RA adoption in primary care.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
431
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
431
01:06Oral Hypoglycemic Agents: Glinides
269
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
269
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
309
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
309
01:23Dipeptidyl Peptidase 4 Inhibitors
269
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
269
01:24Obesity
623
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
623
01:15G Protein-coupled Receptors
13.5K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
13.5K